Leerink Partnrs Predicts Xeris Biopharma FY2025 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Analysts at Leerink Partnrs issued their FY2025 EPS estimates for Xeris Biopharma in a note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn ($0.05) per share for the year. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma’s FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.30 EPS.

XERS has been the subject of several other research reports. Craig Hallum increased their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 7th. Wall Street Zen lowered shares of Xeris Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Leerink Partners increased their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average price target of $6.25.

Xeris Biopharma Price Performance

NASDAQ XERS opened at $4.55 on Monday. The stock has a market capitalization of $711.55 million, a P/E ratio of -10.11 and a beta of 0.71. The firm’s 50-day moving average is $4.54 and its two-hundred day moving average is $4.10. Xeris Biopharma has a 12 month low of $2.03 and a 12 month high of $6.07.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analysts’ expectations of $57.61 million.

Insider Activity

In other news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 6.47% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Legato Capital Management LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth approximately $482,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Xeris Biopharma by 106.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company’s stock worth $581,000 after acquiring an additional 88,224 shares during the last quarter. Vanguard Group Inc. lifted its stake in Xeris Biopharma by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock worth $26,778,000 after acquiring an additional 133,738 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Xeris Biopharma by 10.5% in the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company’s stock worth $384,000 after acquiring an additional 10,748 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the fourth quarter worth approximately $45,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.